Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.49 |
| ▸ | NAAA | Q02083 | 4/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628006 | 1.00 | PRKCA (0.49) | PRKCANAAADGKA | |
| SCHEMBL2099423 | 0.98 | PRKCA (0.47) | PRKCANAAADGKA | |
| SCHEMBL20589363 | 0.92 | PRKCA (0.38) | PRKCANAAA | |
| SCHEMBL1517935 | 0.91 | PRKCA (0.41) | PRKCANAAADGKA | |
| SCHEMBL6551912 | 0.88 | HSD17B10 (0.39) | PRKCA | |
| SCHEMBL371437 | 0.87 | CNR2 (0.41) | PRKCANAAADGKA | |
| SCHEMBL977159 | 0.84 | MAP3K14 (0.38) | — | |
| SCHEMBL9682839 | 0.84 | PRKCA (0.33) | PRKCANAAA | |
| SCHEMBL10727648 | 0.82 | ADRA1A (0.42) | PRKCA | |
| SCHEMBL10877677 | 0.81 | GPR84 (0.43) | PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3084442-B1 | DIAGNOSTIC REAGENTS FOR IMPROVED IN VIVO OR IN VITRO CELL-MEDIATED IMMUNOLOGICAL DIAGNOSIS OF TUBERCULOSIS | STATENS SERUMINSTITUT (DK) | 2021-03-17 | — | — | EP | disclosed |
| US-10641770-B2 | Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis | STATENS SERUM INSTITUT (DK) | 2020-05-05 | — | — | US | disclosed |
| EP-2912056-B1 | M. TUBERCULOSIS VACCINES | STATENS SERUMINSTITUT (DK) | 2020-02-12 | — | — | EP | disclosed |
| EP-3134116-B1 | NEW M.TUBERCULOSIS VACCINES | STATENS SERUMINSTITUT (DK) | 2019-04-03 | — | — | EP | disclosed |
| US-10245313-B2 | DNA motif compounds and methods for inducing specific antibodies and cellular immunity | VERSITECH LIMITED (CN) | 2019-04-02 | — | — | US | disclosed |
| EP-2421557-B1 | A TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATION | STATENS SERUMINSTITUT (DK) | 2018-12-05 | — | — | EP | disclosed |
| US-10004793-B2 | M.tuberculosis vaccines | STATENS SERUM INSTITUT (DK) | 2018-06-26 | — | — | US | disclosed |
| EP-3209784-A1 | DNA MOTIF COMPOUNDS AND METHODS FOR INDUCING SPECIFIC ANTIBODIES AND CELLULAR IMMUNITY | Versitech Limited (CN) | 2017-08-30 | — | — | EP | disclosed |
| EP-2163255-B1 | Tuberculosis vaccines comprising antigens expressed during the latent infection phase | STATENS SERUMINSTITUT (DK) | 2017-08-09 | — | — | EP | disclosed |
| EP-3134116-A1 | NEW M.TUBERCULOSIS VACCINES | Statens Serum Institut (DK) | 2017-03-01 | — | — | EP | disclosed |
| WO-2005061534-A2 | IMPROVED TUBERCULOSIS VACCINES | STATENS SERUM INSTITUT (DK) | 2005-07-07 | — | — | WO | disclosed |
| EP-1523331-A2 | THERAPEUTIC TB VACCINE | Statens Serum Institut (DK) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004099771-A1 | A NEW SPECIFIC EPITOPE BASED IMMUNOLOGICAL DIAGNOSIS OF TUBERCULOSIS | STATENS SERUM INSTITUT (DK) | 2004-11-18 | — | — | WO | disclosed |
| US-20040057963-A1 | Therapeutic TB vaccine | STATENS SERUM INSTITUTE (DK) | 2004-03-25 | — | — | US | disclosed |
| WO-2004006952-A2 | THERAPEUTIC TUBERCULOSIS VACCINES | STATENS SERUM INSTITUT (DK) | 2004-01-22 | — | — | WO | disclosed |
| US-20040013685-A1 | Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis | STATENS SERUM INSTITUT (DK) | 2004-01-22 | — | — | US | disclosed |
| US-20030147897-A1 | M. tuberculosis antigens | STATENS SERUM INSTITUT (DK) | 2003-08-07 | — | — | US | disclosed |
| EP-1278769-A2 | TUBERCULOSIS ANTIGENS AND METHODS OF USE THEREOF | Statens Serum Institut (DK) | 2003-01-29 | — | — | EP | disclosed |
| US-20020176867-A1 | Hybrids of M. tuberculosis antigens | ANDERSEN PETER (DK) | 2002-11-28 | — | — | US | disclosed |
| WO-2001079274-A2 | TUBERCULOSIS ANTIGENS AND METHODS OF USE THEREOF | STATENS SERUM INSTITUT (DK) | 2001-10-25 | — | — | WO | disclosed |